{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-068538","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.076020+00:00","generated_at":"2026-06-18T05:07:08.773859+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Pfizer acquires Seagen for $229/share in $43B cash deal to boost oncology","bullets":["Acquisition of Seagen for $229 per share in cash; total enterprise value approximately $43 billion.","Seagen expected to generate ~$2.2B revenue in 2023 and contribute >$10B risk-adjusted revenue by 2030.","Pfizer to finance with $31B new long-term debt; deal expected to be neutral to slightly accretive to adjusted EPS in 3-4 years.","Transaction expected to close in late 2023 or early 2024, subject to shareholder vote and regulatory approvals.","Baker Bros. Advisors, holding significant Seagen shares, entered voting agreement to support the merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-068538","json":"https://secwatch.observer/filing/0001193125-23-068538.json","markdown":"https://secwatch.observer/filing/0001193125-23-068538.md","text":"https://secwatch.observer/filing/0001193125-23-068538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000119312523068538/0001193125-23-068538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000119312523068538/d408093d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:07:08.773859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"005ad83a2a7c4d436bffd833c6306231aea3ed9c","claim":"PFIZER INC entered into Agreement and Plan of Merger with Seagen Inc. valued at $229.00 per share (effective 2023-03-12).","evidence_excerpt":"On March 12, 2023, Pfizer Inc. (“ Pfizer ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Pfizer, Seagen Inc. (“ Seagen ”) and Aris Merger Sub, Inc., a wholly owned subsidiary of Pfizer (“ Merger Sub ”), pursuant to which, among other things, Merger Sub will be merged with and into Seagen (the “ Merger ”), with Seagen surviving the Merger as a wholly owned subsidiary of Pfizer.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000119312523068538/0001193125-23-068538-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Seagen Inc."},{"label":"Value","value":"$229.00 per share"},{"label":"Effective","value":"2023-03-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}